Michael Gelband’s Warrior Met Coal HCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-10,909
Closed -$1.02M 1770
2026
Q1
$1.02M Buy
+10,909
New +$982K 0.01% 993
2025
Q3
Sell
-30,120
Closed -$1.38M 1733
2025
Q2
$1.38M Buy
+30,120
New +$1.4M 0.01% 864
2023
Q4
Sell
-22,900
Closed -$1.17M 1707
2023
Q3
$1.17M Buy
+22,900
New +$961K 0.01% 905
2023
Q1
Sell
-36,638
Closed -$1.27M 1904
2022
Q4
$1.27M Buy
+36,638
New +$1.3M 0.02% 851
2022
Q3
Sell
-39,911
Closed -$1.22M 2055
2022
Q2
$1.22M Sell
39,911
-60,706
-60% -$2.1M 0.02% 988
2022
Q1
$3.73M Buy
100,617
+53,374
+113% +$1.71M 0.05% 497
2021
Q4
$1.22M Buy
47,243
+28,110
+147% +$676K 0.01% 964
2021
Q3
$445K Buy
+19,133
New +$387K 0.01% 1461
2021
Q2
Sell
-45,650
Closed -$782K 2532
2021
Q1
$782K Buy
+45,650
New +$964K 0.01% 1066
2020
Q4
Sell
-24,281
Closed -$415K 2118
2020
Q3
$415K Buy
+24,281
New +$394K 0.01% 1115
2020
Q2
Sell
-12,698
Closed -$135K 1871
2020
Q1
$135K Buy
+12,698
New +$229K 0.01% 848
2019
Q3
Sell
-30,676
Closed -$801K 1455
2019
Q2
$801K Buy
+30,676
New +$874K 0.03% 320

Other funds holding HCC

Michael Gelband's HCC Position: Q2 2026 in Review

Michael Gelband sold out of Warrior Met Coal (HCC) in Q2 2026, closing a stake of 10,909 shares — an estimated $1.02M sold.

Michael Gelband first reported a position in HCC in Q2 2019 and held it in 12 quarters. The position peaked at $3.73M in Q1 2022. 341 funds tracked by Wall St. Rank hold HCC as of Q2 2026.

  • Michael Gelband reported no remaining Warrior Met Coal position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 10,909 Warrior Met Coal shares in Q2 2026, an estimated $1.02M.
  • Michael Gelband first reported a position in Warrior Met Coal in Q2 2019 and held it in 12 quarters.
  • Michael Gelband's Warrior Met Coal position peaked at $3.73M in Q1 2022.
  • 341 funds tracked by Wall St. Rank held Warrior Met Coal as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.